Education
About Us
Working with TipRanks
Follow Us
FNY - ETF AI Analysis
Top Page
First Trust Mid Cap Growth AlphaDEX Fund (FNY)
Rating:68Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Several of the largest positions, such as MP Materials and Bloom Energy, have delivered strong year-to-date performance, supporting the ETF’s overall returns.
Sector Diversification
The ETF is spread across multiple sectors, including Industrials, Technology, and Health Care, reducing reliance on any single industry.
Healthy Year-to-Date Performance
The fund has shown solid growth so far this year, which may appeal to investors seeking momentum.
Negative Factors
High Geographic Concentration
With nearly all assets invested in U.S. companies, the ETF lacks exposure to international markets, limiting diversification.
Relatively High Expense Ratio
The ETF charges a higher expense ratio compared to many similar funds, which could eat into investor returns over time.
Underperforming Holding
SoundHound AI, one of the top holdings, has shown negative year-to-date performance, slightly dragging on the fund’s overall results.
FNY vs. SPDR S&P 500 ETF (SPY)
AUM474.16M
RegionNorth America
Expense Ratio0.70%
Beta1.07
IssuerFirst Trust
Inception DateApr 19, 2011
Dividend Yield0.51%
Asset ClassEquity
Index TrackedNASDAQ AlphaDEX Mid Cap Growth Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume10,989
30 Day Avg. Volume17,703
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
109.88Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering223
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FNY Summary
The First Trust Mid Cap Growth AlphaDEX Fund (FNY) is an ETF that focuses on mid-sized companies in the U.S. with strong growth potential. It follows the NASDAQ AlphaDEX Mid Cap Growth Index, using a unique strategy to pick stocks based on growth factors. The fund includes companies like Bloom Energy and Symbotic, and covers sectors such as technology, healthcare, and industrials. Investors might consider FNY for its potential to deliver growth and diversify their portfolios with mid-cap stocks. However, it’s important to note that the ETF’s performance can fluctuate with market conditions, and its focus on mid-cap growth companies may make it more volatile than broader market funds.
How much will it cost me?The expense ratio for the First Trust Mid Cap Growth AlphaDEX Fund (FNY) is 0.7%, which means you’ll pay $7 per year for every $1,000 invested. This is higher than average because the fund is actively managed, using a specialized methodology to select and weight stocks for potential growth. Active management typically involves higher costs compared to passively managed funds that track an index.
What would affect this ETF?The First Trust Mid Cap Growth AlphaDEX Fund (FNY) could benefit from positive trends in the U.S. economy, such as technological advancements and increased demand for industrial and healthcare innovations, given its strong exposure to these sectors. However, it may face challenges from rising interest rates, which can negatively impact growth-focused companies, and potential economic slowdowns that could reduce consumer spending and affect cyclical sectors. Regulatory changes or geopolitical tensions could also influence the performance of its top holdings in industries like energy and materials.
FNY Top 10 Holdings
The First Trust Mid Cap Growth AlphaDEX Fund (FNY) leans heavily into industrials and technology, which together make up over 40% of its portfolio. Rising names like Lumentum Holdings and Echostar are providing a lift, thanks to strong technical momentum and promising growth initiatives. However, Guardant Health is lagging slightly, held back by financial instability despite strategic partnerships. The fund’s U.S.-focused approach and mid-cap growth strategy aim to capture companies on the cusp of scaling, though mixed performance in health care and biotech names like Madrigal Pharmaceuticals suggests some bumps along the way.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Lumentum Holdings | 1.76% | $8.36M | $28.07B | 362.04% | 61 Neutral | |
| Ciena | 1.19% | $5.67M | $33.84B | 171.69% | 70 Outperform | |
| Hecla Mining Company | 1.19% | $5.63M | $13.29B | 288.82% | 74 Outperform | |
| Guardant Health | 1.19% | $5.63M | $13.25B | 226.36% | 61 Neutral | |
| Echostar | 1.01% | $4.81M | $30.79B | 363.59% | 57 Neutral | |
| Madrigal Pharmaceuticals | 0.95% | $4.51M | $13.69B | 91.96% | 56 Neutral | |
| PTC Therapeutics | 0.92% | $4.39M | $6.29B | 70.96% | 72 Outperform | |
| AST SpaceMobile | 0.92% | $4.37M | $28.68B | 216.25% | 54 Neutral | |
| TTM Technologies | 0.91% | $4.33M | $7.50B | 183.11% | 77 Outperform | |
| SiTime Corporation | 0.91% | $4.31M | $9.87B | 67.58% | 61 Neutral |
FNY Technical Analysis
Positive
―
Price Trends
91.67
Positive
90.26
Positive
84.22
Positive
Market Momentum
0.71
Negative
57.62
Neutral
79.98
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FNY, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 92.61, equal to the 50-day MA of 91.67, and equal to the 200-day MA of 84.22, indicating a bullish trend. The MACD of 0.71 indicates Negative momentum. The RSI at 57.62 is Neutral, neither overbought nor oversold. The STOCH value of 79.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FNY.
FNY Peer Comparison
Comparison Results
Performance Comparison
FNY
First Trust Mid Cap Growth AlphaDEX Fund
94.04
13.04
16.10%
NUMG
Nuveen ESG Mid-Cap Growth ETF
―
―
―
RFG
Invesco S&P Midcap 400 Pure Growth ETF
―
―
―
TMFM
Motley Fool Mid-Cap Growth ETF
―
―
―
FRTY
Alger Mid Cap 40 ETF
―
―
―
GLRY
Inspire Faithward Mid Cap Momentum ESG ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents